Education
About Us
Working with TipRanks
Follow Us
Basilea Pharmaceutica (CH:BSLN)
:BSLN
RESEARCH TOOLSreports
BSLN Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF36.75 - CHF48.75
Previous CloseN/A
Volume30.09K
Average Volume (3M)53.67K
Market Cap
CHF477.75M
Enterprise ValueCHF560.54M
Total Cash (Recent Filing)CHF12.49M
Total Debt (Recent Filing)CHF128.61M
Price to Earnings (P/E)6.4
Beta0.95
Next Earnings
Aug 19, 2025EPS Estimate
1.89Last Dividend Ex-Date
Apr 11, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)6.40
Shares Outstanding13,172,048
10 Day Avg. Volume54,358
30 Day Avg. Volume53,670
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF84.50Price Target Upside111.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Basilea Pharmaceutica News
---
Bulls Say, Bears Say
Bulls Say
Market ExclusivityMarket exclusivity of Cresemba was extended to October 2027 in the EU and September 2027 in the U.S., providing flexibility for transition to a follow-up antifungal drug.
Regulatory ApprovalsZevtera was approved by the FDA for a broad range of infections and eligible for New-Technology Add-On Payment in the U.S., enhancing its market potential.
Sales PerformanceCresemba continues to perform strongly, with sales in the Asia-Pacific region and China exceeding a pre-defined sales threshold, triggering a $2.5M milestone payment.
Bears Say
Commercialization RisksBasilea announced that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc. for the commercialization of Basilea’s hospital anti-MRSA antibiotic Zevtera in the U.S.
Market Penetration ChallengesRisks include inability to achieve sufficient market penetration with ceftobiprole, particularly in the U.S.
Partnership RisksRisks include inability by Basilea's partners to optimize the value of isavuconazole and ceftobiprole globally and potential setbacks with clinical-stage candidates.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.01%
Mutual Funds
0.11% Other Institutional Investors
90.16% Public Companies and
Individual Investors
BSLN FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
Basilea Pharmaceutica lowest stock price was CHF36.75 and its highest was CHF48.75 in the past 12 months.
What is Basilea Pharmaceutica’s market cap?
Basilea Pharmaceutica’s market cap is CHF477.75M.
When is Basilea Pharmaceutica’s upcoming earnings report date?
Basilea Pharmaceutica’s upcoming earnings report date is Aug 19, 2025 which is in 130 days.
How were Basilea Pharmaceutica’s earnings last quarter?
Basilea Pharmaceutica released its earnings results on Feb 18, 2025. The company reported CHF4.7 earnings per share for the quarter, beating the consensus estimate of CHF3.24 by CHF1.46.
Is Basilea Pharmaceutica overvalued?
According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued.
Does Basilea Pharmaceutica pay dividends?
Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here
What is Basilea Pharmaceutica’s EPS estimate?
Basilea Pharmaceutica’s EPS estimate is 1.89.
How many shares outstanding does Basilea Pharmaceutica have?
Basilea Pharmaceutica has 13,172,048 shares outstanding.
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Basilea Pharmaceutica reported an EPS of CHF4.7 in its last earnings report, beating expectations of CHF3.24. Following the earnings report the stock price went up 8.323%.
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
Currently, no hedge funds are holding shares in CH:BSLN
---
Company Description
Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
---
BSLN Stock 12 Month Forecast
Average Price Target
CHF84.50
▲(111.78% Upside)
Technical Analysis
Molecular Partners AG
―
Idorsia Ltd
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Best Analysts Covering BSLN
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-2.06%
reiterated a buy rating 18 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -2.06% per trade.
---